A Single-arm, Multicenter Phase II Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer in Clinical Efficacy
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer
• Endometrial cancer initially diagnosed as stage III non-operable resectable, stage IV (FIGO, 2009 criteria) after imaging evaluation
• Pathologically confirmed endometrial cancer that looks like endometrial carcinoma
• Patient age ≥18 years and ≤75 years old
• ECOG status score of 0-1
• tolerate surgery and radiotherapy
• Laboratory tests: WBC ≥3.5×109/L, NEU ≥1.5×109/L, PLT ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L.
• ×109/L, serum bilirubin ≤1.5 times the high limit of normal value, transaminase ≤1.5 times the high limit of normal value, BUN ≤1.5 times the high limit of normal value.
⁃ 5 times of the high limit of normal value, BUN, Cr≤normal value;
• Able to follow up and good compliance;
• Able to sign the informed consent form, including compliance with the requirements and restrictions listed in the informed consent form and the program.